FIGURE 5.

An ATRA-mediated CDX2/miR-125b/CBFβ pathway in myeloid cell lines and clinical samples. A, expression levels of CDX2, miR-125b, and CBFβ in NB4 cells using 1 μm ATRA induction for the indicated times. CDX2 was positively correlated with miR-125b expression, whereas CBFβ showed negative co-expression. *, p < 0.05. B and C, expression levels of CDX2 and miR-125b, in 20 pairs of AML-M3 patients before and after therapy. Average expression levels were statistically paired and compared with the average value of patient samples at primary diagnosis without treatment. Data were analyzed using analysis of variance followed by t test for pairwise comparisons to compare the values of means from two related samples in a “diagnosis and complete remission” scenario, Tukey-Kramer's test for multiple comparisons was used to compare the values of means between healthy and AML at diagnosis. D, miR-125b and CBFβ protein levels in 6 pairs of AML-M3 patients at diagnosis (D) and complete remission (CR).